Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC50 values predict SARS‐CoV‐2 neutralising antibody titres

Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC50 values predict SARS‐CoV‐2 neutralising antibody titres

Abstract Objectives The evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) necessitates rapid methods for assessing monoclonal antibody (mAb) potency against emerging variants. Authentic virus neutralisation assays are considered the gold standard for measuring virus‐neutralis...

Full description

Bibliographic Details
Main Authors: Lindsay E Clegg, Oleg Stepanov, Sam Matthews, Tom White, Seth Seegobin, Steven Thomas, Kevin M Tuffy, Mats Någård, Mark T Esser, Katie Streicher, Taylor S Cohen, Anastasia A Aksyuk
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Clinical & Translational Immunology
Subjects:
authentic virus assay
AZD7442 (tixagevimab–cilgavimab)
COVID‐19 monoclonal antibodies
pharmacokinetics
pseudovirus assay
SARS‐CoV‐2 neutralising antibody titres
Online Access:https://doi.org/10.1002/cti2.1517

Internet

https://doi.org/10.1002/cti2.1517

Similar Items